Cargando…

Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma

PURPOSE OF REVIEW: Rituximab-based chemoimmunotherapy has resulted in a marked improvement in the survival of diffuse large B cell lymphoma (DLBCL). We reflect upon the history front-line (1L) therapy and highlight advances in management. RECENT FINDINGS: Since the introduction of R-CHOP, the majori...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kesavan, Murali, Eyre, Toby A., Collins, Graham P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647877/ https://www.ncbi.nlm.nih.gov/pubmed/31254155 http://dx.doi.org/10.1007/s11899-019-00518-8

Ejemplares similares

PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas
por: Barrington, Sally F., et al.
Publicado: (2016)

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022)

B-cell receptor reactivity against Rothia mucilaginosa in nodular lymphocyte-predominant Hodgkin lymphoma
por: Thurner, Lorenz, et al.
Publicado: (2023)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies
por: Boot, Max V., et al.
Publicado: (2022)

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
por: Wagner, Charlotte B., et al.
Publicado: (2023)

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
por: Rossi, Cédric, et al.
Publicado: (2022)

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors
por: Svoboda, Jakub, et al.
Publicado: (2021)

Large B-cell lymphomas
por: Vitolo, Umberto
Publicado: (2019)

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance
por: Barraclough, Allison, et al.
Publicado: (2023)

The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience
por: Kucukyurt, Selin, et al.
Publicado: (2021)

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2
por: Dann, Eldad J, et al.
Publicado: (2021)

Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance
por: Fisher, Kevin E., et al.
Publicado: (2022)

In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
por: Isaev, Keren, et al.
Publicado: (2022)

Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformation
por: Koch, Karoline, et al.
Publicado: (2022)

Impact of positron emission tomography - computed tomography status on progression-free survival for relapsed follicular lymphoma patients undergoing autologous stem cell transplantation
por: Eyre, Toby A., et al.
Publicado: (2022)

ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers: The Israeli/Italian Study
por: Giladi, Odil, et al.
Publicado: (2022)

Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway
por: Zhang, Xiao-Yin, et al.
Publicado: (2022)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy
por: Yahalom, Joachim
Publicado: (2014)

Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
por: García-Sancho, Alejandro Martín, et al.
Publicado: (2022)

Molecular classification of aggressive B-cell lymphoma
por: Bojarczuk, Kamil, et al.
Publicado: (2019)

Aggressive B-cell lymphoma subtyping: a pathologists viewpoint
por: de Jong, Daphne
Publicado: (2019)

Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphoma
por: Song, Joo Y., et al.
Publicado: (2023)

Long non-coding RNA mitophagy and ALK-negative anaplastic lymphoma-associated transcript: a novel regulator of mitophagy in T-cell lymphoma
por: Mularoni, Valentina, et al.
Publicado: (2023)

ABCL-274: Outcomes in Patients with Lymphoproliferative Diseases and COVID-19: Results of a Subgroup Analysis of the CHRONOS19 Registry
por: Gavrilina, Olga, et al.
Publicado: (2021)

ABCL-013: Factors Associated with SARS-CoV-2 Infection and Outcome in Patients with Solid Tumors or Hematological Malignancies: A Single-Center Study
por: Goudsmit, Anouk, et al.
Publicado: (2021)

ABCL-334: Impact of COVID-19 Pandemic on Treatment Duration in Curable Cancers: Comparison of Patients with DLBCL Treated Before and During: A Retrospective Record-Based Study
por: Anandaradje, Annuja, et al.
Publicado: (2021)

IBCL-054 The Effects of an mRNA COVID-19 Vaccine Booster on Immune Responses in Cancer-Bearing Veterans
por: Frankel, Arthur, et al.
Publicado: (2022)

Whole-genome profiling of primary cutaneous anaplastic large cell lymphoma
por: Torres, Armando N. Bastidas, et al.
Publicado: (2021)

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma
por: Li, Lingzhi, et al.
Publicado: (2022)

Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy
por: Demel, Uta M., et al.
Publicado: (2022)

Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma
por: Kameda, Takuro, et al.
Publicado: (2023)

Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
por: Major, Ajay, et al.
Publicado: (2021)

Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma
por: Tanaka, Norio, et al.
Publicado: (2022)

Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
por: Veloza, Luis, et al.
Publicado: (2022)

Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas
por: Leivonen, Suvi-Katri, et al.
Publicado: (2023)

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition
por: Decombis, Salomé, et al.
Publicado: (2022)

CCR6 activation links innate immune responses to mucosa-associated lymphoid tissue lymphoma development
por: Korona, Boguslawa, et al.
Publicado: (2022)

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study
por: Ghione, Paola, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5e2ma8r504eiod8btco9abmil3